Hikma to Acquire EIMC United Pharmaceuticals

Sep 08, 2015

Hikma Pharmaceuticals PLC has agreed to acquire 98% of the share capital of EIMC United Pharmaceuticals (EUP) from a consortium of shareholders. EUP is a pharmaceutical manufacturing company specializing in oncology products.

The acquisition of EUP strengthens Hikma’s position in the fast-growing Egyptian market; brings a portfolio and pipeline in the key strategic areas of oncology and injectables (with the potential to add around 50 products by 2020); adds a manufacturing facility in Egypt, with both oral and injectable lines; and leverages Hikma’s established market position in Egypt and strong sales and marketing team.

Mazen Darwazah, Hikma Vice Chairman and CEO of MENA, said, "Egypt is a very important market for Hikma and we have been rapidly growing our business there over the last few years. Acquiring EUP will further strengthen our market position and be a key driver of future growth. Across the Group, expansion in the areas of oncology and injectables are key strategic priorities and I am very pleased to be developing our capabilities in the MENA region."

Read the full release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments